56 completed. 56 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 56 | Completed 56 |
| Phase 2 | 8 | Completed 8 |
Follow Parathyroid Diseases: new trials by email Literature Review of Parathyroid Diseases trials Research Report on Parathyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
| PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism TransCon PTH, placebo - Hypoparathyroidism, Parathyroid Hormone Deficiency | Phase 3 | Completed | Visen Pharmaceuticals (Shanghai) Co., Ltd. | 81 | 2021-07-28 | 2026-01-16 |
| 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas 18F-Fluorocholine, Positron emission tomography (PET) - Hyperparathyroidism, Primary | Phase 3 | Completed | Thomas Hope | 139 | 2021-06-30 | 2026-04-29 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism TransCon PTH, Placebo - Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Bone Diseases A/S | 84 | 2021-02-16 | 2026-07-07 |
| Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention MIBI scintigraphy, F18-choline PET - Parathyroid Adenoma, Hyperparathyroidism | Phase 3 | Completed | Centre Francois Baclesse | 59 | 2019-09-19 | 2023-08-01 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia KHK7580, Cinacalcet Hydrochloride - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 404 | 2019-04-09 | 2022-04-25 |
| Phase 3 Study of SK-1403 SK-1403, Placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 153 | 2019-01-21 | 2020-03-09 |
| SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis SK-1403 - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 157 | 2018-09-13 | 2020-03-09 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Etelcalcetide, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 637 | 2018-05-15 | 2021-04-30 |
| Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism KHK7580 - Parathyroid Carcinoma, Primary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 18 | 2017-08-30 | 2021-05-27 |
| Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Cinacalcet 30 mg Tablet, Denosumab Inj 60 mg/ml, Placebo tablets - Primary Hyperparathyroidism, Parathyroid Adenoma | Phase 3 | Completed | Peter Vestergaard | 46 | 2017-03-01 | 2021-05-25 |
| Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Sodium zirconium cyclosilicate - Sodium Zirconium Cyclosilicate, Hyperkalemia | Phase 3 | Completed | Guangdong Provincial People's Hospital | 62 | 2016-11-01 | 2022-05-19 |
| 18F-Fluorocholine for the Detection of Parathyroid Adenomas 18F-Fluorocholine, Positron Emission Tomography (PET) - Hyperparathyroidism, Primary | Phase 2 / Phase 3 | Completed | Thomas Hope | 98 | 2016-09-21 | 2021-10-19 |
| Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism eplerenone, amiloride, Placebo - Primary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 69 | 2016-01-01 | 2023-05-03 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 39 | 2015-09-29 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 137 | 2015-09-28 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580, KRN1493 - Secondary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 634 | 2015-09-01 | 2017-03-24 |
Showing 20 of 56. Sign in to see all of them.
Hyperparathyroidism, Secondary (32) · Renal Insufficiency, Chronic (15) · Hyperparathyroidism (12) · Kidney Failure, Chronic (11) · Hypoparathyroidism (9) · Hyperparathyroidism, Primary (8) · Hypocalcemia (6) · Kidney Diseases (5) · Hypercalcemia (4) · Parathyroid Neoplasms (4) · Renal Insufficiency (4) · Vitamin D Deficiency (4) · Chronic Kidney Disease-Mineral and Bone Disorder (2) · Endocrine System Diseases (2)
Endocrine System Diseases (54) · Hyperparathyroidism (36) · Pathological Conditions, Signs and Symptoms (25) · Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Male Urogenital Diseases (24) · Urogenital Diseases (24) · Urologic Diseases (24) · Chronic Disease (23) · Disease Attributes (23) · Pathologic Processes (23) · Kidney Diseases (19) · Nutritional and Metabolic Diseases (17) · Renal Insufficiency (17)
Cinacalcet (16) · etelcalcetide hydrochloride (7) · paricalcitol (5) · Calcifediol (3) · Magnetic Resonance Spectroscopy (2) · Parathyroid Hormone (2) · Sugars (2) · Teriparatide (2) · fluorocholine (2) · 1 alpha-hydroxyergocalciferol (1) · Amiloride (1) · Calcitriol (1) · Calcium (1) · Calcium Carbonate (1) · Cholecalciferol (1)
Amgen (15) · Kyowa Kirin Co., Ltd. (6) · Shire (4) · AbbVie (prior sponsor, Abbott) (2) · OPKO Health, Inc. (2) · OPKO IP Holdings II, Inc. (2) · Pathalys Pharma (2) · Sanwa Kagaku Kenkyusho Co., Ltd. (2) · Thomas Hope (2) · Abbott (1) · Ascendis Pharma Bone Diseases A/S (1) · Brigham and Women's Hospital (1) · Centre Francois Baclesse (1) · Columbia University (1) · Creighton University (1)
United States (26) · Hungary (10) · Poland (10) · Canada (9) · France (9) · Italy (9) · Japan (9) · Belgium (8) · Germany (8) · Russia (8) · Spain (8) · Australia (6) · China (6) · Czechia (6) · Denmark (6)
Joel Melnick, MD (4) · John P Bilezikian, MD (2) · Thomas Hope, MD (2) · Anand Vaidya, MD MMSc (1) · Ann Eldred, MD (1) · Joan M Lappe, Ph.D (1) · Julius Simoni Leere, MD (1) · Kazuya Kobayashi, BA (1) · Kenneth R. Phelps, M.D. (1) · Lars Rejnmark, MD,PhD,DrMed (1) · Lars Rolighed, MD (1) · Peter Vestergaard, DMSc (1) · Shuangxin Liu, Ph.D (1)
PMID 36018496, PMID 32738041, PMID 35696069, PMID 35974422, PMID 40576086, PMID 15689407, PMID 16105056, PMID 17556697, PMID 18793528, PMID 24128439, PMID 24622413, PMID 25029424, PMID 25404192, PMID 25685872, PMID 25710802, PMID 25851955, PMID 25887067, PMID 26059012, PMID 26684150, PMID 26951967, PMID 27080930, PMID 28332096, PMID 28942334, PMID 29099947, PMID 29525393, PMID 29779023, PMID 29972871, PMID 30859218, PMID 30955188, PMID 31369089, PMID 32333877, PMID 33283264, PMID 33413316, PMID 34003226, PMID 35018442, PMID 35176038, PMID 36512619, PMID 37696667, PMID 38691316, PMID 38900416, PMID 39136801, PMID 39969301, PMID 41078042
2023 (2), 2008 (1), 2014 (1), 2016 (1), M01RR000042 (1), P50AR054086 (1), R01DK069350 (1)